Developing new generation medicines for Central Nervous System (CNS) diseases and disorders with high unmet need

VistaGen Therapeutics (NASDAQ: VTGN) is a clinical-stage biopharmaceutical company developing new generation medicines for multiple CNS diseases and disorders with high unmet need including major depressive disorder, social anxiety disorder and suicidal ideation.

Each of VistaGen's CNS pipeline candidates has potential as a convenient, at-home treatment with rapid-onset therapeutic benefits and an exceptional safety profile - without psychological or other side effects and safety concerns often associated with current and potential new generation medications for certain highly-prevalent CNS diseases and disorders.

Our Pipeline

Going Beyond Current Treatment Options for Depression and Social Anxiety Disorder

Learn more about our CNS Pipeline

Experienced Leadership

Our experienced leadership team has a proven track record of developing innovative medicines to treat a wide range of CNS diseases and disorders.

Meet Our Team

Stock Information

View Detailed Stock Info
Nasdaq: VTGN Symbol
Day Range
52 Week Range

Email Updates

Be the first to receive news, events & updates Sign Up